“The Parkinson’s Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- Parkinson’s Disease pipeline products will significantly revolutionize the Parkinson’s Disease market dynamics”

 

The Parkinson’s Disease market report provides current treatment practices, Parkinson’s Disease emerging drugs, market share of individual therapies, and current and forecasted 7MM Parkinson’s Disease market size from 2019 to 2032. The report also covers current Parkinson’s Disease treatment market practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.

 

Key Takeaways from the Parkinson’s Disease Market Research Report

• The Parkinson’s disease market size in the 7MM will increase at a CAGR of 11.2% due to the increase in diagnosed prevalent cases of the disease and the anticipated launch of emerging Parkinson’s disease therapies.
• The leading companies working in the Parkinson’s Disease Market include Newron Pharmaceuticals, Kyowa Kirin, AbbVie, Acadia Pharmaceuticals, Inc., Acorda Therapeutics Inc, Hisamitsu Pharmaceutical Co. Inc., Sunovion Pharmaceuticals, Adamas Pharmaceuticals, Neurocrine Biosciences, Teva Pharmaceuticals, Amneal Pharmaceuticals, Cerevel Therapeutics, Pharma Two B, Mitsubishi Tanabe Pharma, Amneal Pharmaceuticals, Addex Pharma S.A., Ipsen, Annovis Bio Inc., and others.
• Promising Parkinson’s Disease Pipeline Therapies in the various stages of development include BIIB122, LY03003 ( Rotigotine, extended-release microspheres), Istradefylline 20 mg or 40 mg, and others.
• September 2023: Prevail Therapeutics announced a study of phase 1 & 2 clinical trials for LY3884961, Methylprednisolone, and Sirolimus. Study J3Z-MC-OJAA is a Phase 1/2a, multicenter, open-label, ascending dose, first in-human study that will evaluate the safety of intracisternal LY3884961 administration in patients with moderate to severe Parkinson’s disease with at least 1 pathogenic GBA1 mutation. Two dose level cohorts of LY3884961 are planned (Dose Level 1 and Dose Level 2). The duration of the study is 5 years.
• September 2023: FAScinate Therapeutics Inc. announced a study of phase 2 clinical trials for KM-819. The goal of this study is to test KM-819 in halting or slowing the progression of Parkinson’s disease. The study evaluates the safety and tolerability of multiple ascending doses of KM-819 in healthy older adults and participants with Parkinson’s disease.

 

Discover more about therapies set to grab major Parkinson’s Disease Market Share @ Parkinson’s Disease Market Size

 

Parkinson’s Disease Overview

Parkinson’s disease is a progressive disorder that is caused by the degeneration of nerve cells in the part of the brain called the substantia nigra, which controls movement. The cause of Parkinson’s disease remains unknown but it has long been hypothesized that exposure to environmental risk factors may be one cause, along with an inherited susceptibility. The majority of cases are thought to arise sporadically, although up to 20% of people with Parkinson’s disease also have a first-degree relative with Parkinson’s disease.

 

Parkinson’s Disease Epidemiology Segmentation in the 7MM

• Parkinson’s Disease Diagnosed Prevalent Population
• Parkinson’s Disease Gender-specific Diagnosed Prevalent Population
• Parkinson’s Disease Age-specific Diagnosed Prevalent Population
• Parkinson’s Disease Stage-specific Diagnosed Prevalent Population

 

Download the report to understand which factors are driving Parkinson’s Disease Epidemiology Trends @ Parkinson’s Disease Epidemiological Insights

 

Parkinson’s disease Emerging Drugs

• Tavapadon: Cerevel Therapeutics/Pfizer

 

Parkinson’s Disease Market Outlook

Accurate diagnosis, and pharmacologic treatments are all important aspects of managing Parkinson’s disease. There are different types of medications available in Parkinson’s disease market. Available medicines cannot reverse Parkinson’s disease; however, they are used to manage symptoms that affect movement in people with Parkinson’s disease. DelveInsight’s market forecast focus on the market revenue generated by pharmacological therapies (including all the currently used therapies) prescribed for the management of Parkinson’s disease and doesn’t comprise the revenue generated by devices &/or surgical procedures.

 

To learn more about Parkinson’s Disease Treatment options, visit @ Parkinson’s Disease Drugs

 

Parkinson’s Disease Drugs Market

For the purpose of study, the Parkinson’s disease drugs market is categorized on the basis of medications treat Parkinson’s disease including, levodopa dopamine agonists, MAO-B inhibitors, COMT inhibitors, amantadine, anticholinergics, and adenosine A2a antagonists.

 

Parkinson’s Disease Market Access and Reimbursement

According to Yang et al. (2020), there were approximately 1 million individuals diagnosed with Parkinson’s disease in 2017, and a total economic burden of USD 51.9 billion. The total burden of Parkinson’s disease includes direct medical costs of USD 25.4 billion and USD 26.5 billion in indirect and nonmedical costs, including an indirect cost of USD 14.2 billion (persons with Parkinson’s disease [PWP] and caregiver burden combined), nonmedical costs of USD 7.5 billion, and USD 4.8 billion due to disability income received by PWPs. The Medicare program bears the largest share of excess medical costs, as most Parkinson’s disease patients are over age 65. The projected prevalence will be more than 1.6 million with a projected total economic burden surpassing USD 79 billion by 2037. The costs of informal caregivers comprise an important subgroup of the total costs and are often greater than direct costs. Furthermore, since most patients require informal care, these costs pose a significant burden.

 

Learn more about the Parkinson’s Disease Pipeline Therapies in clinical trials @ Parkinson’s Disease Market Landscape

 

Scope of the Parkinson’s Disease Market Research Report

• Coverage- 7MM
• Study Period- 2019-2032
• Parkinson’s Disease Companies- Newron Pharmaceuticals, Kyowa Kirin, AbbVie, Acadia Pharmaceuticals, Inc., Acorda Therapeutics Inc, Hisamitsu Pharmaceutical Co. Inc., Sunovion Pharmaceuticals, Adamas Pharmaceuticals, Neurocrine Biosciences, Teva Pharmaceuticals, Amneal Pharmaceuticals, Cerevel Therapeutics, Pharma Two B, Mitsubishi Tanabe Pharma, Amneal Pharmaceuticals, Addex Pharma S.A., Ipsen, Annovis Bio Inc., and others.
• Parkinson’s Disease Pipeline Therapies- BIIB122, LY03003 ( Rotigotine, extended-release microspheres), Istradefylline 20 mg or 40 mg, and others.
• Parkinson’s Disease Market Dynamics: Parkinson’s Disease Market Drivers and Barriers
• Parkinson’s Disease Market Access and Reimbursement, Unmet Needs, and Future Perspectives

 

Discover more about Parkinson’s Disease Drugs in development @ Parkinson’s Disease Ongoing Clinical Trials Analysis

 

Table of Content

1. Key Insights

2. Report Introduction

3. Parkinson’s disease Market Overview at a Glance

4. Executive Summary of Parkinson’s disease

5. Key Events

6. Parkinson’s disease Epidemiology and Market Methodology

7. Parkinson’s disease Background and Overview

8. Parkinson’s disease Epidemiology and Patient Population

9. Parkinson’s disease Patient Journey

10. Parkinson’s disease Marketed Products

11. Emerging Parkinson’s disease Therapies

12. Parkinson’s disease: The 7MM Analysis

13. Parkinson’s disease KOL Views

14. Parkinson’s disease SWOT Analysis

15. Parkinson’s disease Unmet Needs

16. Parkinson’s disease Market Access and Reimbursement

17. Acronyms and Abbreviations

18. Appendix

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight 

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers and acquisitions. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking